Protagonist Therapeutics Reports Granting of Inducement Awards

Rhea-AI Summary

Protagonist Therapeutics (Nasdaq: PTGX) reported that on July 15, 2026, it granted equity inducement awards to three recently hired employees under its Amended and Restated Inducement Plan, originally adopted May 29, 2018 and amended in 2020 and 2022.

The employees received, in aggregate, options for 12,600 shares of common stock and RSUs for 3,330 shares. The stock options have an exercise price of $135.46, equal to the July 15, 2026 Nasdaq Global Market closing price. Options vest over four years (25% after one year, then monthly over three years), while RSUs vest 25% annually over four years. The compensation committee approved these awards as material inducements to employment in accordance with Nasdaq Rule 5635(c)(4).

AI-generated analysis. How Rhea-AI works. Not financial advice.

Market Context

Viewed against an active S-3ASR shelf and a record of net insider selling over the last 90 days, the...

Analysis

Viewed against an active S-3ASR shelf and a record of net insider selling over the last 90 days, these small inducement awards look like routine compensation. With moderate short positioning, investors may watch for any larger equity usage or follow-on offerings.

Key Figures

Stock options granted: 12,600 shares RSUs granted: 3,330 shares Option exercise price: $135.46 +5 more

8 metrics

Stock options granted 12,600 shares Aggregate options in inducement awards to three new employees

RSUs granted 3,330 shares Aggregate restricted stock units in inducement awards

Option exercise price $135.46 Equal to PTGX July 15, 2026 Nasdaq Global Market close

Option vesting period 4 years 25% after one year, remainder in monthly installments over three years

RSU vesting period 4 years One-fourth of RSU shares vesting annually

Plan adoption date May 29, 2018 Protagonist Therapeutics Amended and Restated Inducement Plan adoption

Plan amendment dates Feb 18, 2020; Feb 15, 2022 Subsequent amendments to the inducement plan

Current share price $135.46 Pre-headline price vs. which inducement option strike was set

Historical Context

5 past events · Latest: Jul 01 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 01	Inducement awards	Neutral	+5.2%	Stock-based inducement options and RSUs granted to three new employees.
Jun 16	Inducement awards	Neutral	+0.7%	Equity inducement options and RSUs issued under the inducement plan.
Jun 01	Clinical data presentations	Positive	-4.7%	Phase 3 VERIFY and long-term rusfertide data scheduled for EHA congress.
May 28	Conference participation	Neutral	-1.8%	Management to present at two major June healthcare investment conferences.
May 05	1Q26 earnings report	Positive	+4.8%	Q1 2026 results with FDA approval, milestone payment, and strong cash runway.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows modest reactions to inducement-award announcements, with larger moves tied to earnings and major clinical or regulatory updates.

Key Terms

restricted stock units, nasdaq global market

2 terms

restricted stock units financial

"and restricted stock units (RSUs) to acquire 3,330 shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq global market financial

"per-share closing price of Protagonist Therapeutics common stock on the Nasdaq Global Market"

The Nasdaq Global Market is a section of the stock exchange where larger, well-established companies are listed and publicly traded. It functions like a marketplace where investors can buy and sell shares of these companies, providing them with access to capital and opportunities for growth. Its role is important because it helps investors identify and invest in reputable companies with strong financial backgrounds.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEWARK, CA / ACCESS Newswire / July 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on July 15, 2026, it granted inducement awards to three recently hired employees in accordance with the terms of their employment offer letters. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.

The new employees received, in the aggregate, options to purchase 12,600 shares of Protagonist Therapeutics common stock and restricted stock units (RSUs) to acquire 3,330 shares of Protagonist Therapeutics common stock. The exercise price of the options is $135.46, which is equal to the per-share closing price of Protagonist Therapeutics common stock on the Nasdaq Global Market on July 15, 2026. The shares subject to each option vest over a four-year period, with 25 percent of the shares subject to the option vesting on the first anniversary of each employee's date of hire and the remainder vesting in equal monthly installments over three years thereafter. One-fourth of the shares underlying the RSUs will vest annually over a four-year period. The awards were approved by the compensation committee of the Company's board of directors and were granted as a material inducement to each employee entering into employment with the Company in accordance with Nasdaq Marketplace Rule 5635(c)(4).

About Protagonist

Protagonist Therapeutics is a discovery-through-late-stage development biopharmaceutical company with a proprietary technology platform that enables de novo discovery of peptide therapeutics. Two novel peptides derived from Protagonist's proprietary discovery platform are at or near commercialization. ICOTYDE™ (icotrokinra), licensed to Johnson & Johnson company Janssen Biotech, Inc., is the first and only targeted oral peptide that precisely blocks the Interleukin-23 receptor. ICOTYDE was launched in the U.S. in March 2026, is approved for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age or older and is in Phase 3 development for psoriatic arthritis, ulcerative colitis and Crohn's disease. ICOTYDE was jointly discovered by Protagonist and Johnson & Johnson scientists, with Protagonist having primary responsibility for the development of ICOTYDE through Phase 1, and Johnson & Johnson assuming responsibility for further development and commercialization. Protagonist also discovered and led development through Phase 3 of rusfertide, a first-in-class hepcidin mimetic peptide licensed to Takeda Pharmaceuticals. An NDA for rusfertide for the treatment of polycythemia vera is under priority review with the FDA. The Company also has a number of clinical and preclinical programs addressing clinically and commercially validated targets, including an oral IL-17 antagonist peptide, obesity dual and triple agonists, an oral hepcidin functional mimetic, and the recently announced IL-4 and amylin programs.

More information on Protagonist, its pipeline drug candidates, and clinical studies can be found on the Company's website at https://www.protagonist-inc.com.

Investor Relations Contact

Corey Davis, Ph.D.
LifeSci Advisors
cdavis@lifesciadvisors.com
+1 212 915 2577

Media Relations Contact

Virginia Amann
ENTENTE Network of Companies
virginiaamann@ententeinc.com
+1 833 500 0061 ext 1

View the original press release on ACCESS Newswire

SOURCE: Protagonist Therapeutics

View the original press release on ACCESS Newswire

FAQ

What inducement awards did Protagonist Therapeutics (PTGX) grant on July 15, 2026?

Protagonist Therapeutics granted stock options for 12,600 shares and RSUs for 3,330 shares to three new employees. According to Protagonist Therapeutics, these equity awards were granted as material inducements to employment under its Amended and Restated Inducement Plan.

What is the exercise price of the new PTGX stock options granted as inducement awards?

The exercise price of the new Protagonist Therapeutics stock options is $135.46 per share. According to Protagonist Therapeutics, this price equals the per-share closing price of its common stock on the Nasdaq Global Market on July 15, 2026.

How do the PTGX inducement stock options granted in July 2026 vest?

The inducement stock options vest over four years for each employee. According to Protagonist Therapeutics, 25% of the option shares vest on the first anniversary of the hire date, with the remainder vesting in equal monthly installments over the following three years.

What is the vesting schedule for the Protagonist Therapeutics (PTGX) RSUs granted to new employees?

The RSUs granted as inducement awards vest over a four-year period. According to Protagonist Therapeutics, one-fourth of the shares underlying each RSU award will vest annually, resulting in 25% vesting each year for four years.

Under which plan were the July 2026 PTGX inducement awards granted?

The July 2026 inducement awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan. According to Protagonist Therapeutics, this plan was adopted on May 29, 2018 and later amended on February 18, 2020 and February 15, 2022.

How do the July 2026 PTGX inducement awards comply with Nasdaq rules?

The inducement awards were approved as material inducements to employment in line with Nasdaq requirements. According to Protagonist Therapeutics, the compensation committee granted them pursuant to Nasdaq Marketplace Rule 5635(c)(4), which governs equity awards to new employees outside shareholder-approved plans.